| Literature DB >> 23882129 |
Mark de Been1, Willem van Schaik, Lu Cheng, Jukka Corander, Rob J Willems.
Abstract
Reasons for the rising clinical impact of the bacterium Enterococcus faecium include the species' rapid acquisition of adaptive genetic elements. Here, we focused on the impact of recombination on the evolution of E. faecium. We used the recently developed BratNextGen algorithm to detect recombinant regions in the core genome of 34 E. faecium strains, including three newly sequenced clinical strains. Recombination was found to have a significant impact on the E. faecium genome: of the original 1.2 million positions in the core genome, 0.5 million were predicted to have been affected by recombination in at least one strain. Importantly, strains in one of the two major E. faecium clades (clade B), which contains most of the E. faecium human gut commensals, formed the most important reservoir for donating foreign DNA to the second major E. faecium clade (clade A), which contains most of the clinical isolates. Also, several genomic regions were found to mainly recombine in specific hospital-associated E. faecium strains. One of these regions (the epa-like locus) likely encodes the biosynthesis of cell wall polysaccharides. These findings suggest a crucial role for recombination in the emergence of E. faecium as a successful hospital-associated pathogen.Entities:
Keywords: BratNextGen; antibiotic resistance; comparative genomics; nosocomial pathogen; phylogenomics; whole-genome sequencing
Mesh:
Substances:
Year: 2013 PMID: 23882129 PMCID: PMC3762198 DOI: 10.1093/gbe/evt111
Source DB: PubMed Journal: Genome Biol Evol ISSN: 1759-6653 Impact factor: 3.416
Whole-Genome Sequenced E. faecium Strains Available in July 2012
| Strain | Source | Country | Year | Reported Resistances | MLST | GenBank BioProject Codes |
|---|---|---|---|---|---|---|
| E155 | Clinical isolate (faeces) | USA | 1995 | AMP, VAN; | 17 | PRJNA192879 |
| E525 | Clinical isolate (wound) | AUS | 1998 | AMP, VAN; | 17 | PRJNA192893 |
| E1165 | Clinical isolate (wound) | ITA | 1997 | AMP; | 17 | PRJNA192894 |
| Aus0004 | Clinical isolate (blood) | AUS | 1998 | VAN; | 17 | PRJNA87025 |
| C68 | Clinical isolate (faeces) | USA | 1996 | AMP, VAN; | 16 | PRJNA40855 |
| TX0082 | Clinical isolate (blood) | USA | 1999 | AMP, VAN | 17 | PRJNA61137 |
| E1162 | Clinical isolate (blood) | FRA | 1997 | AMP; | 17 | PRJNA47013 |
| TX0133A | Clinical isolate (blood) | USA | 2006 | VAN; | 17 | PRJNA61139 |
| TX0133a01 | Clinical isolate (blood) | USA | 2006 | VAN; | 17 | PRJNA61143 |
| TX0133a04 | Clinical isolate (blood) | USA | 2006 | 17 | PRJNA61129 | |
| TX0133B | Clinical isolate (blood) | USA | 2006 | 17 | PRJNA61141 | |
| TX0133C | Clinical isolate (blood) | USA | 2006 | VAN; | 17 | PRJNA61131 |
| 1,231,410 | Clinical isolate (skin and soft tissue) | USA | 2005 | AMP, VAN; | 17 | PRJNA55719 |
| DO (TX16) | Clinical isolate (blood) | USA | 1992 | AMP; | 18 | PRJNA54089 |
| 1,231,502 | Clinical isolate (blood) | USA | 2005 | AMP, VAN; | 203 | PRJNA55713 |
| U0317 | Clinical isolate (urine) | NLD | 2005 | AMP; | 78 | PRJNA47349 |
| 1,230,933 | Clinical isolate (wound) | USA | 2005 | AMP, VAN; | 18 | PRJNA55701 |
| 1,231,408 | Clinical isolate (blood) | USA | 2005 | AMP | 582 | PRJNA55721 |
| E4453 | Commensal isolate (dog faeces) | NLD | 2008 | AMP | 192 | PRJNA179597 |
| E1071 | Commensal isolate (faeces) | NLD | 2000 | VAN | 32 | PRJNA47015 |
| E4452 | Commensal isolate (dog faeces) | NLD | 2008 | AMP | 266 | PRJNA179613 |
| E1679 | Clinical isolate (vascular catheter) | BRA | 1998 | AMP, VAN; | 114 | PRJNA47347 |
| E1636 | Clinical isolate (blood) | NLD | 1961 | AMP | 106 | PRJNA47345 |
| D344SRF | Spontaneous mutant of strain D344R | USA | ? | — | 25 | PRJNA46237 |
| TC 6 | Transconjugant | USA | ? | 25 | PRJNA41101 | |
| E1039 | Commensal isolate (faeces) | NLD | 1998 | — | 42 | PRJNA47011 |
| 1,231,501 | Clinical isolate (blood) | USA | 2005 | — | 52 | PRJNA55715 |
| LCT-EF90 | Derived from | SWI | ? | — | 76 | PRJNA141665 |
| E980 | Commensal isolate (faeces) | NLD | 1998 | — | 94 | PRJNA47017 |
| Com15 | Commensal isolate (faeces) | USA | 2007 | — | 583 | PRJNA55725 |
| 1,141,733 | Clinical isolate (blood) | USA | 2005 | — | 52 | PRJNA55717 |
| PC4.1 | Commensal isolate (faeces) | AUS | 2008 | — | 720 | PRJNA46979 |
| Com12 | Commensal isolate (faeces) | USA | 2006 | — | 107 | PRJNA55723 |
| TX1330 | Commensal isolate (faeces) | USA | 1994 | — | 107 | PRJNA55481 |
aAll isolates were of human origin unless stated otherwise.
bWe only list reported ampicillin (AMP) and vancomycin (VAN) resistances here.
cMLST data were extracted from the MLST website (Imperial College, London; http://efaecium.mlst.net/, last accessed August 3, 2013) or were determined using MLST v1.6 (Larsen et al. 2012).
dIsolates collected from the faeces of hospitalized patients. Strains E155 and C68 are regarded as clinical isolates because they were representative clones of hospital outbreaks. Strain C68 is described in Carias et al. (1998).
eTransconjugant of mating between strains C68 and D344SRF.
fThis strain was derived from the E. faecium type strain and was cultured at 15 and 37 °C for more than 4 weeks prior to DNA isolation and sequencing. The E. faecium type strain was first deposited to culture collections in 1946, but the impact of this extensive subculturing of this derivative has not been characterized.
FImpact of recombination on E. faecium phylogeny and quantification and determination of origins of recombinant sequences. (A) Midpoint rooted phylogenetic tree (RAxML) built from an alignment of 85,488 variable positions in the E. faecium core genome. No recombination filtering was applied. (B) Midpoint rooted phylogenetic tree (RAxML) build from an alignment of 46,823 nonrecombinant variable positions in the E. faecium core genome. Numbers near branches indicate percentage bootstrap support: only numbers <95% are indicated and only for main branches (for all bootstrap supports, see supplementary fig. S2, Supplementary Material online). Branch lengths correspond to the scale bar, in units of changes/nucleotide position. (C) Predicted levels and origin of recombinant sequences per strain.
FDistribution of recombinant sequences over the Enterococcus faecium core genome. Recombinant sequences were plotted onto the E. faecium Aus0004 core genome, as determined in this study, starting with the first core gene (efau0004_00001, dnaA) on the left and proceeding to the last core gene (efau0004_02867) on the right. Black segments below the recombinant regions indicate recombination hotspots.
FEnterococcus faecium epa-like locus variants and recombination signals detected in locus variant four. Gene clusters of the four epa-like locus variants are displayed for representative strains Aus0004 (variant four), 1,231,408 (variant three), Com12 (variant two), and Com15 (variant one). The occurrence of the four variants across the other strains is indicated to the left. Core genomic genes are connected by pink shades. Other orthologous and paralogous genes are indicated by numbers. Part of the conserved upstream epa-like locus (epaL–epaO and epaR) is indicated by L, M, N, O, and R. The downstream epa-like extension is indicated by blue solid lines above the illustration of locus variant four. Locus variant four was predicted to be affected by large core genomic recombination events 2 and 3 (indicated by solid black lines above the locus variant four illustration) that potentially spanned multiple accessory genes (indicated by dashed gray lines). Genes are color-coded according to functional category. Drawings are to scale.